Pfizer Holds Number One Spot And Takeda Breaks The Top 10

Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future. 

Finance chart
Big pharma ups and downs • Source: Shutterstock

Takeda Pharmaceuticals International GmbH grew into a top 10 pharmaceutical company for the first time in 2019 in a sign of how drug developers often rely on M&A to fuel game-changing growth. The company ranked as the number nine pharmaceutical player in the world in the Scrip 100 rankings, based on 2019 pharmaceutical revenues of $30.19bn, moving up substantially in the rankings from number 16 in 2018 and number 18 in 2017.

It was the acquisition of the rare disease specialist Shire that powered Takeda into the top 10. The change represents...

More from Business Strategy

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.